Fig. 4From: Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot studyPerfusion fractions of the responders and non-responders at baseline, and after 1, 2, and 4 weeks of sorafenib treatment. No significant changes or differences were observed between the 2 groupsBack to article page